UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the ~~Securities Exchange Act of 1934~~

~~Date~~Securities ofExchange ~~Report~~Act ~~(Date~~ of ~~earliest event reported): December 13, 2024~~1934

Date of Report (Date of earliest event reported): April 15, 2025

BIOMERICA, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-37863

95-2645573

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

17571 Von Karman Ave. Irvine, California		92614
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (949) 645-2111

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading ~~symbol(s)~~Symbol	Name of each exchange on which registered
Common Stock, par value $.08	BMRA	Nasdaq Capital Market
Common Stock, par value $0.08	BMRA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 53.0703 ~~Submission~~Material ofModification ~~Matters~~ to aRights ~~Vote~~ of Security Holders.

~~Biomerica,~~The ~~Inc.~~information ~~(the~~contained ~~“Company”) held its 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) on December 13, 2024, at its corporate headquarters~~ in ~~Irvine,~~Item ~~California~~5.03 As of ~~October~~this ~~16,~~Current ~~2024,~~Report ~~the~~on ~~record~~Form ~~date~~8-K ~~for~~is ~~the~~incorporated ~~2024~~herein ~~Annual Meeting, the Company had 16,821,646 shares of common stock outstanding and entitled to vote, of which 10,287,675 shares of common stock were present in person or represented~~ by ~~proxy and entitled to vote at the 2024 Annual Meeting~~reference. ~~The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the 2024 Annual Meeting.~~

~~Proposal~~Item No5.03 1:Amendment ~~The Company’s stockholders elected each of the five nominees named below~~ to ~~serve~~Articles ~~on the Company’s Board~~ of ~~Directors~~Incorporation ~~(the “Board”) until the next annual meeting of stockholders of the Company and until his~~ or ~~her~~Bylaws: ~~successor has~~Change ~~been~~in ~~elected~~Fiscal ~~and qualified or until his or her earlier resignation, death or removal.~~Year

Nominee	Votes For		Votes Withheld		Broker Non-votes
Zackary Irani		4,784,611		169,339		5,524,703
Allen Barbieri		4,757,823		196,127		5,524,703
Jane Emerson, M.D., Ph.D.		4,611,714		342,236		5,524,703
Catherine Coste		4,779,659		174,291		5,524,703
David Moatazedi		4,772,930		181,020		5,524,703

As previously disclosed, at Biomerica, Inc.’s (the “Company”) 2024 Annual Meeting of Stockholders held on December 13, 2024 (the “2024 Annual Meeting”), the stockholders of the Company approved a proposal to authorize the Company’s Board of Directors (the “Board”) to amend the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to effect a reverse stock split (the “Reverse Stock Split”) at a ratio between one-for-three and one-for-fifteen, with the ultimate ratio to be determined by the Board in its sole discretion. On April 2, 2025, the Board approved the Reverse Stock Split at a ratio of one-for-eight.

~~Proposal~~On ~~No.~~April 215, 2025, the Company filed an amendment to the Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, to be effective at 12:01 ~~The~~a.m. Eastern Time on April 21, 2025. On April 21 2025, the Company’s ~~stockholders~~common ~~approved,~~stock will begin trading on a ~~non~~split-~~binding~~adjusted ~~advisory~~ basis under a new CUSIP, 09061H406. The Reverse Split will proportionately reduce the ~~compensation~~number ~~paid~~of outstanding shares of the Company’s common stock from approximately 20,366,095 to ~~our~~2,545,762 ~~named~~(subject ~~executive~~to ~~officers~~rounding of shares). The Reverse Split will not change the number of authorized shares of the Company’s common stock or preferred stock as set forth in our Certificate of Incorporation, as amended.

Votes For				Votes Against				Votes Abstaining				Broker Non-Votes
	4,613,080				275,661				65,209				5,524,703

No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will instead automatically have their interests rounded up to the next whole share, after aggregating all the fractional interests of a holder resulting from the Reverse Stock Split.

~~Proposal~~The ~~No.~~foregoing 3:description ~~The~~of ~~Company’s~~the ~~stockholders~~Amendment ~~ratified~~does not purport to be complete and is qualified in its entirety by the ~~selection~~full text of ~~Haskell~~the &Amendment, a ~~White~~copy ~~LLP~~of which is filed as ~~the~~Exhibit ~~Company’s~~3.1 ~~independent registered~~to ~~public~~this ~~accounting~~Current ~~firm~~Report ~~for~~on ~~the~~Form ~~fiscal~~8-K ~~year~~and ~~ending~~is ~~May~~incorporated ~~31,~~herein ~~2025~~by reference.

Votes For				Votes Against				Votes Abstaining				Broker Non-Votes
	10,287,675				94,547				96,431				—

Item 7.01 Regulation FD Disclosure

~~Proposal~~On ~~No.~~April 4:16, ~~The~~2025, the Company’s ~~stockholders~~issued ~~approved~~a press release announcing the ~~2024~~Reverse Stock ~~Incentive~~Split, ~~Plan~~a copy of which is furnished as an exhibit to this report.

Votes For				Votes Against				Votes Abstaining				Broker Non-Votes
	4,186,308				730,217				37,425				5,524,703

The information in this Item 7.01, including Exhibit 99.1 to this report, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 7.01 and Exhibit 99.1 shall not be incorporated by reference into any filing under the Exchange Act or the Securities Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

~~Proposal~~Forward-Looking No. 5: The Company’s stockholders approved the amendment to the Company’s First Amended and Restated Certificate of Incorporation to authorize the Board, at their discretion, to effect a reverse stock split of the Company’s common stock.Statements

Votes For				Votes Against				Votes Abstaining				Broker Non-Votes
	9,789,531				558,553				130,569				—

All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements may be identified by words such as “will” and “expected”, or the negative of such terms, or other comparable terminology, and include statements about the Reverse Stock Split and the impacts, if any, on the Company’s common stock. Forward-Looking statements are statements that are not historical facts. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein due to many factors. These forward-looking statements and such risks, uncertainties and other factors speak only as of the date of this Current Report on Form 8-K, and the Company expressly disclaims any obligation or undertaking to update or revise and forward-looking statement contained herein, or to reflect any change in our expectations with regard thereto or any other change in events, conditions, or circumstances on which any such statement is based, except to the extent otherwise required by applicable law.

~~Proposal~~Item No9.01 6:Financial ~~The~~Statements ~~Company’s stockholders approved the amendment to the Company’s First Amended~~ and ~~Restated Certificate of Incorporation to authorize the Board, at their discretion, to effect an increase in the number of authorized shares of the Company’s common stock.~~Exhibits

Votes For				Votes Against				Votes Abstaining				Broker Non-Votes
	9,619,013				770,675				88,965				—

(d) Exhibits

Proposal No. 7: The Company’s stockholders approved an adjournment of the Annual Meeting, if necessary or appropriate, including to establish a quorum.

Number		Description
3.1		Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation
99.1		Press Release dated April 16, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Votes For				Votes Against				Votes Abstaining				Broker Non-Votes
	9,905,692				360,840				212,121				—

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIOMERICA, INC.
Date: December 17, 2024	By:	/s/ Zackary S. Irani
Date: April 16, 2025	By:	/s/ Zackary S. Irani
		Zackary S. Irani
		Zackary S. Irani Chief Executive Officer
		Chief Executive Officer

Filing Compare · BIOMERICA INC